FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2896411390> ?p ?o ?g. }

• W2896411390 endingPage "e651" @default.
• W2896411390 startingPage "e651" @default.
• W2896411390 abstract "Multiple adjuvant treatment options are available for patients with FIGO stage II endometrial cancer. Treatment options may include vaginal brachytherapy (VBT), external beam radiation (EBRT), and/or chemotherapy. The purpose of this abstract was to assess failure patterns following various combinations of adjuvant treatment. A total of 71 patients were identified with FIGO stage II endometrial cancer following transabdominal hysterectomy and bilateral salpingo-oophorectomy (TAH-BSO). Pelvic lymph node dissection was carried out in all patients with a paraaortic lymph node dissection in n = 33 (46%). Sarcoma histologies were excluded from this study. Patients were treated between March 2008 to January 2017 and followed until January 2018. Details including clinical characteristics, treatments, and outcomes were extracted from retrospective chart review and radiologic examinations. Our patient cohort most commonly had grade 3 tumors (n = 33, 46%), followed by grade 2 (n = 23, 32%), and grade 1 (n = 15; 21%). Greater than 50% myometrial invasion was noted in the majority (n = 40, 56%) with LVSI noted in n = 24 (34%). Median age of patients at the time of surgical resection was 64 years old (range: 34 - 93). Grade 1 - 2 tumors were treated with no radiation, VBT, EBRT, or both VBT and EBRT in 18%, 31%, 11%, and 39% of cases, respectively. Chemotherapy was received by 18% of patients with grade 1 - 2 tumors. Grade 3 tumors were treated with no radiation, VBT, or both VBT and EBRT in 33%, 27%, and 39% of cases, respectively. Chemotherapy was received by the majority of patients with grade 3 tumors (67%). Median follow-up was 24.5 months. Two pelvic recurrences were noted in grade 3 tumors with an overall 36-month pelvic control rate of 97%. The most common site of failure was distant with 12-, 24-, and 36-month distant control rates of 98%, 86%, and 80%, respectively. Grade 3 tumors were more likely to have distant recurrence than grades 1-2 tumors (HR 6.9, 95% CI 1.6 – 47.1; p = 0.007) and receipt of chemotherapy improved distant control in grade 3 tumors (HR 0.15, 95% CI 0.02 - 0.93; p = 0.04). The 12-, 24-, and 36-month local (vaginal) control rates were 98%, 98%, and 92%, respectively. Receipt of either VBT or EBRT reduced the risk of local recurrence with 24-month local control rates of 100% vs. 93% (p = 0.04), respectively. In our cohort of FIGO stage II patients following TAH-BSO with lymph node dissection, local control was improved by the receipt of either VBT of EBRT. The most common site of failure was distant. Novel strategies are needed to improve distant control in grade 3 tumors." @default.
• W2896411390 created "2018-10-26" @default.
• W2896411390 creator A5006894236 @default.
• W2896411390 creator A5019100561 @default.
• W2896411390 creator A5022224126 @default.
• W2896411390 creator A5034222906 @default.
• W2896411390 creator A5035397040 @default.
• W2896411390 creator A5044655732 @default.
• W2896411390 creator A5046174015 @default.
• W2896411390 creator A5046372733 @default.
• W2896411390 creator A5062612957 @default.
• W2896411390 creator A5087302565 @default.
• W2896411390 creator A5026615550 @default.
• W2896411390 date "2018-11-01" @default.
• W2896411390 modified "2023-09-25" @default.
• W2896411390 title "Clinical Outcomes Following Adjuvant Management of FIGO Stage II Endometrial Cancer" @default.
• W2896411390 doi "https://doi.org/10.1016/j.ijrobp.2018.07.1768" @default.
• W2896411390 hasPublicationYear "2018" @default.
• W2896411390 type Work @default.
• W2896411390 sameAs 2896411390 @default.
• W2896411390 citedByCount "0" @default.
• W2896411390 crossrefType "journal-article" @default.
• W2896411390 hasAuthorship W2896411390A5006894236 @default.
• W2896411390 hasAuthorship W2896411390A5019100561 @default.
• W2896411390 hasAuthorship W2896411390A5022224126 @default.
• W2896411390 hasAuthorship W2896411390A5026615550 @default.
• W2896411390 hasAuthorship W2896411390A5034222906 @default.
• W2896411390 hasAuthorship W2896411390A5035397040 @default.
• W2896411390 hasAuthorship W2896411390A5044655732 @default.
• W2896411390 hasAuthorship W2896411390A5046174015 @default.
• W2896411390 hasAuthorship W2896411390A5046372733 @default.
• W2896411390 hasAuthorship W2896411390A5062612957 @default.
• W2896411390 hasAuthorship W2896411390A5087302565 @default.
• W2896411390 hasBestOaLocation W28964113901 @default.
• W2896411390 hasConcept C121608353 @default.
• W2896411390 hasConcept C126322002 @default.
• W2896411390 hasConcept C126838900 @default.
• W2896411390 hasConcept C141071460 @default.
• W2896411390 hasConcept C146357865 @default.
• W2896411390 hasConcept C151730666 @default.
• W2896411390 hasConcept C167135981 @default.
• W2896411390 hasConcept C2775862295 @default.
• W2896411390 hasConcept C2775908122 @default.
• W2896411390 hasConcept C2777088508 @default.
• W2896411390 hasConcept C2777416452 @default.
• W2896411390 hasConcept C2779013556 @default.
• W2896411390 hasConcept C2779494336 @default.
• W2896411390 hasConcept C2780849966 @default.
• W2896411390 hasConcept C2781212463 @default.
• W2896411390 hasConcept C509974204 @default.
• W2896411390 hasConcept C71924100 @default.
• W2896411390 hasConcept C86803240 @default.
• W2896411390 hasConceptScore W2896411390C121608353 @default.
• W2896411390 hasConceptScore W2896411390C126322002 @default.
• W2896411390 hasConceptScore W2896411390C126838900 @default.
• W2896411390 hasConceptScore W2896411390C141071460 @default.
• W2896411390 hasConceptScore W2896411390C146357865 @default.
• W2896411390 hasConceptScore W2896411390C151730666 @default.
• W2896411390 hasConceptScore W2896411390C167135981 @default.
• W2896411390 hasConceptScore W2896411390C2775862295 @default.
• W2896411390 hasConceptScore W2896411390C2775908122 @default.
• W2896411390 hasConceptScore W2896411390C2777088508 @default.
• W2896411390 hasConceptScore W2896411390C2777416452 @default.
• W2896411390 hasConceptScore W2896411390C2779013556 @default.
• W2896411390 hasConceptScore W2896411390C2779494336 @default.
• W2896411390 hasConceptScore W2896411390C2780849966 @default.
• W2896411390 hasConceptScore W2896411390C2781212463 @default.
• W2896411390 hasConceptScore W2896411390C509974204 @default.
• W2896411390 hasConceptScore W2896411390C71924100 @default.
• W2896411390 hasConceptScore W2896411390C86803240 @default.
• W2896411390 hasIssue "3" @default.
• W2896411390 hasLocation W28964113901 @default.
• W2896411390 hasOpenAccess W2896411390 @default.
• W2896411390 hasPrimaryLocation W28964113901 @default.
• W2896411390 hasRelatedWork W2069132912 @default.
• W2896411390 hasRelatedWork W2411961033 @default.
• W2896411390 hasRelatedWork W2486140844 @default.
• W2896411390 hasRelatedWork W2811076898 @default.
• W2896411390 hasRelatedWork W2993575405 @default.
• W2896411390 hasRelatedWork W2997874316 @default.
• W2896411390 hasRelatedWork W3023151437 @default.
• W2896411390 hasRelatedWork W4251733923 @default.
• W2896411390 hasRelatedWork W4295234634 @default.
• W2896411390 hasRelatedWork W4300604927 @default.
• W2896411390 hasVolume "102" @default.
• W2896411390 isParatext "false" @default.
• W2896411390 isRetracted "false" @default.
• W2896411390 magId "2896411390" @default.
• W2896411390 workType "article" @default.